Activation of mitogen-activated protein kinase extracellular signal-related kinase in head and neck squamous cell carcinomas after irradiation as part of a rescue mechanism

Head and Neck

Volumn 33, Issue 10, 2011, Pages 1448-1457

  Affolter, Annette ^a   Fruth, Kai ^a   Brochhausen, Christoph ^b   Schmidtmann, Irene ^b   Mann, Wolf J ^a   Brieger, Jürgen ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

ERK; head and neck cancer; MAP kinase pathway; radiation resistance; VEGF

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MITOGEN ACTIVATED PROTEIN KINASE; VASCULOTROPIN;

ARTICLE; CANCER RADIOTHERAPY; CELL LINE; CONTROLLED STUDY; ENZYME ACTIVATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; XENOGRAFT;

ANIMALS; BUTADIENES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM TRANSPLANTATION; NITRILES; RADIOTHERAPY DOSAGE; SIGNAL TRANSDUCTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80053011704     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21623     Document Type: Article

References (44)

1. Grant S, Qiao L, Dent P,. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control for cell growth and survival. Front Biosci 2002; 7: 376-389.
2. Schmidt-Ullrich RK, Dent P, Grant S, Mikkelsen RB, Valerie K,. Signal transduction and cellular radiation responses. Radiat Res 2000; 153: 245-257.
3. Timke C, Zieher H, Roth A, et al. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 2008; 14: 2210-2219.
4. Zingg D, Riesterer O, Fabbro D, Glanzmann C, Bodis S, Pruschky M,. Differential activation of the phosphatidylinositol 3-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells. Cancer Res 2004; 64: 5398-5406.
5. Narang H, Krishna M,. Mitogen-activated protein kinases: specificity of response to dose of ionizing radiation in liver. J Radiat Res 2004; 45: 213-220.
6. Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S,. MAPK pathways in radiation response. Oncogene 2003; 22: 5885-5896.
7. Brieger J, Schroeder P, Gosepath J, Mann WJ,. Vascular endothelial growth factor and basic fibroblast growth factor are released by squamous cell carcinoma cell lines after irradiation and increase resistance to subsequent irradiation. Int J Mol Med 2005; 16: 159-164.
8. Bancroft CC, Chen Z, Dong G, et al. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res 2001; 7: 435-442.
9. Jung YD, Nakano K, Liu W, et al. Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. Cancer Res 1999; 59: 4804-4807.
10. Lichter AS, Lawrence TS,. Recent advances in radiation oncology. N Engl J Med 1995; 332: 371-379.
11. Coleman CN, Stevenson MA,. Biologic basis for radiation oncology. Oncology 1996; 10: 399-411.
12. Maity A, Kao GD, Muschel R.J, McKenna WG,. Potential molecular targets for manipulating the radiation response. Int J Radiat Oncol Biol Phys 1997; 37: 639-653.
13. Welkoborsky HJ, Jacob R, Riazimand SH, Bernauer HS, Mann WJ,. Molecular biologic characteristics of seven new cell lines of squamous cell carcinomas of the head and neck and comparison to fresh tumor tissue. Oncology 2003; 65: 60-71.
14. Vlachtsis K, Brieger J, Kim DW, et al. Quantitative analysis of VEGF-isoforms in head and neck squamous cell carcinoma cell lines: relation to xenotransplantability and tumour progression in mice. Oncol Rep 2002; 9: 1133-1138.
15. Remmele W, Stegner HE,. Recommendation for uniform definition as an immunoreactive score (IRS) for immunohistochemical estrogen receptors detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8: 138-140.
16. Hagan M, Wang K, Hanley JR, Park JS, Dent P,. Ionizing radiation-induced mitogen-activated protein (MAP) kinase activation in DU145 prostate carcinoma cells: MAP kinase inhibition enhances radiation-induced cell killing and G2/M-phase arrest. Radiat Res 2000; 153: 371-383.
17. Dent P, Reardon DB, Park JS, et al. Radiation-induced release of transforming growth factor α activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999; 10: 2493-2506.
18. Carter S, Auer KL, Birrer M, et al. Potentiation of ionizing radiation induced cell killing by inhibition of the mitogen activated protein (MAP) kinase cascade in A431 human squamous carcinoma cells. Oncogene 1998; 16: 2787-2796.
19. Contessa JN, Reardon DB, Todd D, et al. The inducible expression of dominant negative EGFR-CD533 results in radiosensitization of human mammary carcinoma cells. Clin Cancer Res 1999; 5: 405-411.
20. Sewing A, Wiseman B, Lloyd AC, Land H,. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 1997; 17: 5588-5597.
21. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M,. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 1997; 17: 5598-5611.
22. Auer KL, Park JS, Seth P, et al. Prolonged activation of the mitogen activated protein (MAP) kinase pathway promotes DNA synthesis in primary hepatocytes from p21Cip-1/WAF1-null mice, but not in hepatocytes from p16INK4a-null mice. Biochem J 1998; 336: 551-560.
23. Dent P, Jarvis WD, Birrer MJ, Fisher PB, Schmidt-Ullrich RK, Grant S,. The roles of signaling by the p42/44 mitogen-activated protein (MAP) kinase pathway: a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity. Leukemia 1998; 12: 1843-1850.
24. Tombes R, Auer KL, Mikkelsen R, et al. The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic. Biochem J 1998; 330: 1451-1460.
25. Warenius HM, Jones MD, Thompson CC,. Exit from G2 phase after 2 Gy gamma irradiation is faster in radiosensitive human cells with high expression of the RAF1 proto-oncogene. Radiat Res 1996; 146: 485-493.
26. Gokhale PC, Soldatenkov V, Wang FH, Rahman A, Dritschilo A, Kasid U,. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer. Gene Ther 1997; 4: 1289-1299.
27. 2/M checkpoint arrest in cells exposed to ionizing radiation. J Biol Chem 1999; 274: 2732-2742.
28. Loda M, Capodieci P, Mishra R, et al. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am J Pathol 1996; 149: 1553-1564.
29. Magi-Galluzzi C, Mishra R, Fiorentino M, et al. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab Invest 1997; 76: 37-51.
30. Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995; 55: 4182-4187.
31. Ito Y, Sasaki Y, Horimoto M, et al. Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 1998; 27: 951-958.
32. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 813-822.
33. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ,. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999; 59: 279-284.
34. Mandell JW, Hussaini IM, Zecevic M, Weber MJ, VandenBerg SR,. In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am J Pathol 1998; 153: 1411-1423.
35. Gee JM, Barroso AF, Ellis IO, Robertson JF, Nicholson RI,. Biological and clinical associations of c-jun activation in human breast cancer. Int J Cancer 2000; 89: 177-186.
36. Mishima K, Yamada E, Masui K, et al. Overexpression of the ERK/MAP kinases in oral squamous cell cracinoma. Mod Pathol 1998; 11: 886-891.
37. Albanell J, Cordony-Servat J, Rojo F, et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001; 61: 6500-6510.
38. Raman M, Cobb MH,. MAP kinase modules: many roads home. Curr Biol 2003; 13: 886-888.
39. Seiwert TY, Cohen EE,. Targeting angiogenesis in head and neck cancer. Semin Oncol 2008; 35: 274-285.
40. Moriyama M, Kumagai S, Kawashiri S, Kojima K, Kakihara K, Yamamoto E,. Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma. Oral Oncol 1997; 33: 369-374.
41. Denhart BC, Guidi AJ, Tognazzi K, Dvorak HF, Brown LF,. Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. Lab Invest 1997; 77: 659-664.
42. Petruzzelli GJ, Benefield J, Taitz AD, et al. Heparin-binding growth factor(s) derived from head and neck squamous cell carcinomas induce endothelial cell proliferations. Head Neck 1997; 19: 576-582.
43. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59: 3374-3378.
44. Kohno M, Pouyssegur J,. Pharmacological inhibitors of the ERK signalling pathway: application as anticancer drugs. Prog Cell Cycle Res 2003; 5: 219-224.